NASDAQ : COGT
Cogent Biosciences, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 31.96 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 5.55B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 5.19B |
| Enterprise Value | 4.65B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 173.52M |
| Shares Outstanding | 173.57M |
| Shares Change (YoY) | +37.58% |
| Shares Change (QoQ) | +5.41% |
| Owned by Insiders (%) | 0.56% |
| Owned by Institutions (%) | 117.75% |
| Float | 172.56M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 62.94 |
| PB Ratio | 11.39 |
| P/TBV Ratio | 11.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 13.57 |
| Quick Ratio | 13.36 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -75.14 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -109.74% |
| Return on Assets (ROA) | -43.84% |
| Return on Invested Capital (ROIC) | -49.01% |
| Return on Capital Employed (ROCE) | -50.19% |
| Weighted Average Cost of Capital (WACC) | 5.79% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.46M |
| Employee Count | 258 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.31 |
| 52-Week Price Change | +83.74% |
| 50-Day Moving Average | 32.29 |
| 200-Day Moving Average | 35.66 |
| Relative Strength Index (RSI) | 41.32 |
| Average Volume (20 Days) | 2,184,263 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 19.66M |
| Short Previous Month | 19.46M |
| Short % of Shares Out | 11.33% |
| Short % of Float | 11.39% |
| Short Ratio (days to cover) | 8.48 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -389.09M |
| Pretax Income | -377.18M |
| Net Income | -377.18M |
| EBITDA | -386.46M |
| EBIT | -389.09M |
| Earnings Per Share (EPS) | -$2.43 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 792.30M |
| Total Debt | 244.26M |
| Net Cash | 548.04M |
| Net Cash Per Share | $3.16 |
| Equity (Book Value) | 532.39M |
| Book Value Per Share | 2.72 |
| Working Capital | 745.52M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -307.55M |
| Capital Expenditures | -1.70M |
| Depreciation & Amortization | 2.64M |
| Net Borrowing | 168.47M |
| Free Cash Flow | -309.24M |
| FCF Per Share | -$1.78 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -37.58% |
| Shareholder Yield | -37.58% |
| Earnings Yield | -8.13% |
| FCF Yield | -5.81% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $55.82 |
| Price Target Difference | 86.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Nov 9, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:4 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |